Back

Is extraplatelet production of thromboxane B2 in acute myocardial infarction the explanation for higher rates of adverse cardiovascular events ?

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 6 - Antiplatelet therapy Thrombosis and platelets ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Edyta Stodolkiewicz-Nowarska

Jagiellonian University Medical College, John Paul II Hospital, Krakow (Poland)

22 More presentations in this session

Presentation thumbnail
Comparison of the new oral P2Y12 inhibitor (Prasugrel/Ticagrelor) to Clopidogrel in type 2 diabetes mellitus patients with AMI
Doctor M. Kim (Daejeon, KR)
Abstract
Presentation thumbnail
Impact of antiplatelet drugs on cholesterol level of platelet lipid rafts
Mrs V. Rabani (Besancon, FR)
Abstract Slides
Presentation thumbnail
Optical coherence tomography assessment of in-stent thrombus immediately after percutaneous coronary intervention in patients pretreatment with Prasugrel compared to Clopidogre
Doctor Y. Katayama (Wakayama, JP)
Abstract Slides
Presentation thumbnail
Circadian variation of platelets inhibition with ticagrelor
Doctor S. Fournier (Lausanne, CH)
Abstract Slides
Presentation thumbnail
Platelet reactivity is gender and age related
Mr G. Vos (Nieuwegein, NL)
Abstract Slides

Access the full session

Session thumbnail
Poster session 6 - Antiplatelet therapy

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources